RIFAMYCINE CHIBRET
THEA
Identification
- Active ingredient (INN)
- RIFAMYCINE
- Internal code
- 17 D 033
- Country of Origin
- France
- Pharmaceutical form
- Eye Drops Solution
- Prescription List
- Highly Regulated (List I)
- Packaging
- FL/10ML
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
Local antibacterial treatment of conjunctivitis, keratitis and corneal ulcers due to rifamycin sensitive germs; official recommendations for the appropriate use of antibacterials should be taken into account.
Associated Conditions
Do not inject, swallow.
The eye drops should not be given as a peri.
- or intraocular injection.
This eye drops should not be used when wearing soft contact lenses, hydrophilic, which can be permanently coloured.
In addition, if the eye is infected, the contact lens should not be worn during the duration of the treatment.
Patients should be informed that this eye drops (cloths, glasses and others) should be handled with caution.
This medicine contains an organomeric compound that can cause allergic reactions.
This medicine contains "sulphite" and can cause severe allergic reactions and bronchospasm.
In the case of treatment with another eye drops, space 15 minutes for instillations.
In the event of hypersensitivity, discontinuation of treatment.
In the absence of rapid improvement or prolonged treatment, regular medical monitoring with bacteriological controls with study of the sensitivity of the germ, allows for detection of resistance to the product and possible adjustment of treatment.
Mechanism of Action
Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration
Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration Agglomeration A.
Adverse Effects
Risk of hypersensitivity reaction.
- Due to the presence of potassium disulfite, risk of allergic reactions including reactions.
- Anaphylactics and bronchospasms.
This medicinal product contains a preservative, thiomersal (an organomeric compound); therefore hypersensitivity reactions may occur.
Reporting suspected adverse reactions
Reporting suspected adverse reactions after authorisation is important.
It allows for continuous monitoring of the benefit/risk ratio of the medicinal product.
Health professionals report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and Network of Regional Pharmacovigilance Centres.